Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Seladelpar · Livdelzi

Small molecule · Agonist of PPAR-delta (PPARD) · developed by Gilead Sciences

Approved FDA

GILD Developer

1 Registered trials

What is Seladelpar?

Seladelpar (Livdelzi) is an oral peroxisome proliferator-activated receptor (PPAR)-delta agonist that reduces bile acid synthesis by activating PPARδ in the liver, inducing FGF21-dependent downregulation of CYP7A1.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Livdelzi
Drug type: Small molecule
Targets: PPAR-delta (PPARD), CYP7A1 (secondary target)
Mechanism: Agonist of PPAR-delta (PPARD)
Pathways: bile acid synthesis, FGF21 signaling
Therapy area: Gastroenterology
Developer: Gilead Sciences, Inc (GILD)
FDA status: Approved as Livdelzi, NDA217899 · FDA label

✅ FDA-approved uses

Primary biliary cholangitis (PBC)

From the indications section of the FDA label (version of Feb 3, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06051617	Phase 3	Primary Biliary Cholangitis	Recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Primary Biliary Cholangitis

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Tenofovir Disoproxil FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Seladelpar

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z